TFF Pharmaceuticals, Inc. and Catalent announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF Pharmaceuticals' patented Thin Film Freezing (TFF) technology. Under the agreement, Catalent will provide its scale-up expertise and manufacturing capabilities to TFF Pharmaceuticals as its preferred development and manufacturing partner, and Catalent will be able to offer its customers access to the innovative TFF technology, which has the potential to increase the adoption of the pulmonary route for the systemic delivery of biotherapeutics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 USD | +1.33% | -2.71% | -56.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.55% | 7.58M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- TFFP Stock
- News TFF Pharmaceuticals, Inc.
- TFF Pharmaceuticals, Inc. and Catalent Announce Their Collaboration Agreement Focused on Generation, Testing and Manufacture of Dry Powder Formulations for Range of Biotherapeutics